Net Profit Margin: 23.09%
Is the net profit margin high or low?
The net profit margin of 23.09% is 34% below its 5-year average of 35.07%, near the low end of its 5-year range (5.81%–226.73%).
As of Monday, June 29, 2026. 22.17% above its 12-month average of 18.90%.
EW Profit Margin
Reported quarterly profit margin; no daily interpolation.
EW Average Net Profit Margin Chart
EW Current vs Average Net Profit Margin Chart
EW Net Profit Margin Metrics
NET PROFIT MARGIN
23.09%
NET PROFIT MARGIN AVG TTM
18.90%
NET PROFIT MARGIN AVG 3Y
25.13%
NET PROFIT MARGIN AVG 5Y
26.53%
NET PROFIT MARGIN AVG 10Y
25.17%
NET PROFIT MARGIN AVG 15Y
21.66%
NET PROFIT MARGIN AVG 20Y
19.22%
CURRENT VS TTM AVG
+22.17%
CURRENT VS 3Y AVG
-8.11%
CURRENT VS 5Y AVG
-12.95%
CURRENT VS 10Y AVG
-8.26%
CURRENT VS 15Y AVG
+6.60%
CURRENT VS 20Y AVG
+20.16%
EW Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.61B | 23.09% | 18.90% | 25.13% | 26.53% |
| Cencora, Inc. (COR)vs › | $55.67B | 0.78% | 0.49% | 0.59% | 0.22% |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | 0.62% | 0.54% | 0.18% | -0.22% |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 5.33% | 8.06% | 8.30% | 8.27% |
| Humana Inc. (HUM)vs › | $46.08B | 0.82% | 0.97% | 1.82% | 2.53% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 24.63% | 23.70% | 22.66% | 22.55% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 29.65% | 31.24% | 32.06% | 36.64% |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 17.24% | 12.73% | 10.54% | 8.34% |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 19.55% | 19.27% | 18.75% | 17.94% |
| Medline Inc. (MDLN)vs › | $32.87B | 3.31% | 4.39% | 2.42% | 2.42% |
Margin Comparison
Operating Margin
27.6%
Net Profit Margin
23.1%
Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Net Profit Margin FAQ
- What is the net profit margin for Edwards Lifesciences Corporation (EW)?
- The net profit margin for EW stock is 23.09%.
- Is Edwards Lifesciences Corporation's net profit margin high or low?
- The net profit margin of 23.09% is 34% below its 5-year average of 35.07%, near the low end of its 5-year range (5.81%–226.73%).
- What is the TTM average net profit margin for Edwards Lifesciences Corporation (EW)?
- The TTM average net profit margin for EW stock is 18.90%.
- What is the 3Y average net profit margin for Edwards Lifesciences Corporation (EW)?
- The 3Y average net profit margin for EW stock is 25.13%.
- What is the 5Y average net profit margin for Edwards Lifesciences Corporation (EW)?
- The 5Y average net profit margin for EW stock is 26.53%.
- What is the 10Y average net profit margin for Edwards Lifesciences Corporation (EW)?
- The 10Y average net profit margin for EW stock is 25.17%.
- What is the 15Y average net profit margin for Edwards Lifesciences Corporation (EW)?
- The 15Y average net profit margin for EW stock is 21.66%.
- What is the 20Y average net profit margin for Edwards Lifesciences Corporation (EW)?
- The 20Y average net profit margin for EW stock is 19.22%.
EW Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 23.09% |
| 2025-12-31 | 5.81% |
| 2025-09-30 | 18.74% |
| 2025-06-30 | 21.52% |
| 2025-03-31 | 25.34% |
| 2024-12-31 | 27.83% |
| 2024-09-30 | 226.73% |
| 2024-06-30 | 26.24% |
| 2024-03-31 | 26.46% |
| 2023-12-31 | 29.21% |
| 2023-09-30 | 30.96% |
| 2023-06-30 | 23.71% |
| 2023-03-31 | 23.33% |
| 2022-12-31 | 29.55% |
| 2022-09-30 | 26.04% |
| 2022-06-30 | 29.58% |
| 2022-03-31 | 27.86% |
| 2021-12-31 | 25.22% |
| 2021-09-30 | 25.96% |
| 2021-06-30 | 35.57% |
| 2021-03-31 | 27.80% |
| 2020-12-31 | 25.97% |
| 2020-09-30 | 28.50% |
| 2020-06-30 | -13.18% |
| 2020-03-31 | 27.52% |
| 2019-12-31 | 23.87% |
| 2019-09-30 | 25.11% |
| 2019-06-30 | 22.29% |
| 2019-03-31 | 25.15% |
| 2018-12-31 | 0.72% |
| 2018-09-30 | 24.92% |
| 2018-06-30 | 29.96% |
| 2018-03-31 | 23.09% |
| 2017-12-31 | 4.02% |
| 2017-09-30 | 20.71% |
| 2017-06-30 | 22.11% |
| 2017-03-31 | 26.06% |
| 2016-12-31 | 20.65% |
| 2016-09-30 | 19.12% |
| 2016-06-30 | 16.67% |
| 2016-03-31 | 20.51% |
| 2015-12-31 | 20.97% |
| 2015-09-30 | 19.19% |
| 2015-06-30 | 18.27% |
| 2015-03-31 | 20.90% |
| 2014-12-31 | 17.67% |
| 2014-09-30 | 15.57% |
| 2014-06-30 | 95.11% |
| 2014-03-31 | 11.54% |
| 2013-12-31 | 14.14% |
| 2013-09-30 | 15.50% |
| 2013-06-30 | 18.04% |
| 2013-03-31 | 28.97% |
| 2012-12-31 | 17.85% |
| 2012-09-30 | 15.45% |
| 2012-06-30 | 14.07% |
| 2012-03-31 | 14.18% |
| 2011-12-31 | 14.67% |
| 2011-09-30 | 12.50% |
| 2011-06-30 | 13.47% |
| 2011-03-31 | 15.80% |
| 2010-12-31 | 16.51% |
| 2010-09-30 | 13.76% |
| 2010-06-30 | 15.74% |
| 2010-03-31 | 14.01% |
| 2009-12-31 | 13.73% |
| 2009-09-30 | 22.57% |
| 2009-06-30 | 14.16% |
| 2009-03-31 | 19.30% |
| 2008-12-31 | 12.30% |
| 2008-09-30 | 10.84% |
| 2008-06-30 | 12.12% |
| 2008-03-31 | 6.13% |
| 2007-12-31 | 5.39% |
| 2007-09-30 | 11.13% |
| 2007-06-30 | 12.80% |
| 2007-03-31 | 12.57% |
| 2006-12-31 | 7.79% |
| 2006-09-30 | 11.24% |
| 2006-06-30 | 13.51% |
| 2006-03-31 | 17.90% |
| 2005-12-31 | 15.46% |
| 2005-09-30 | -1.83% |
| 2005-06-30 | 5.38% |
| 2005-03-31 | 12.53% |
| 2004-12-31 | 10.92% |
| 2004-09-30 | 5.52% |
| 2004-06-30 | 10.87% |
| 2004-03-31 | -26.43% |
| 2003-12-31 | 8.43% |
| 2003-09-30 | 11.89% |
| 2003-06-30 | 9.69% |
| 2003-03-31 | 6.82% |
| 2002-12-31 | 10.68% |
| 2002-09-30 | -10.49% |
| 2002-06-30 | 17.71% |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian